很少有证据表明如何最好地管理非小细胞肺癌(nsclc)患者的临床情况很少。包括寡转移酶,寡头进展,和伪进程。在每种情况下,肿瘤学家必须考虑如何最好地平衡疗效与生活质量,同时最大限度地延长每一行的治疗时间,并确保患者仍然有资格接受以后的选择,包括临床试验登记。
召集了一个专家小组来定义临床问题。使用基于案例的演示文稿,每个临床场景的共识实践建议是通过集中产生的,基于证据的讨论。
提出了治疗策略和最佳实践或共识建议,确定了共识领域和不确定领域。
在每种情况下,治疗必须量身定做以适合个体患者,但是为了扩大和最大限度地利用每一行治疗,同时为以后的治疗保留治疗选择。应鼓励患者参与检查这些问题的临床试验。
Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including oligometastases,
oligoprogression, and pseudoprogression. In each of those scenarios, oncologists have to consider how best to balance efficacy with quality of life, while maximizing the duration of each line of therapy and ensuring that patients are still eligible for later options, including clinical trial enrolment.
An expert panel was convened to define the clinical questions. Using case-based presentations,
consensus practice recommendations for each clinical scenario were generated through focused, evidence-based discussions.
Treatment strategies and best-practice or
consensus recommendations are presented, with areas of
consensus and areas of uncertainty identified.
In each situation, treatment has to be tailored to suit the individual patient, but with the intent of extending and maximizing the use of each line of treatment, while keeping treatment options in reserve for later lines of therapy. Patient participation in clinical trials examining these issues should be encouraged.